Which has preferable valuation and earnings, BRKR or TECH?

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bruker $3.44B 2.61 -$8.60M -$0.24 N/A Bio-Techne $1.22B 9.16 $73.40M $0.69 103.42

Is BRKR or TECH more profitable?

Bio-Techne has a net margin of 9.05% compared to Bruker's net margin of -0.65%. Bio-Techne's return on equity of 13.57% beat Bruker's return on equity. Company Net Margins Return on Equity Return on Assets Bruker -0.65% 11.60% 4.25% Bio-Techne 9.05% 13.57% 10.66%

Does the media refer more to BRKR or TECH?

In the previous week, Bio-Techne had 2 more articles in the media than Bruker. MarketBeat recorded 7 mentions for Bio-Techne and 5 mentions for Bruker. Bruker's average media sentiment score of 1.63 beat Bio-Techne's score of 0.53 indicating that Bruker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bio-Techne 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or TECH?

In the previous week, Agilent Technologies had 6 more articles in the media than Bio-Techne. MarketBeat recorded 13 mentions for Agilent Technologies and 7 mentions for Bio-Techne. Agilent Technologies' average media sentiment score of 0.90 beat Bio-Techne's score of 0.53 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECH or CRL?

In the previous week, Bio-Techne and Bio-Techne both had 7 articles in the media. Charles River Laboratories International's average media sentiment score of 1.13 beat Bio-Techne's score of 0.53 indicating that Charles River Laboratories International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, TECH or DHR?

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.16 $73.40M $0.69 103.42 Danaher $24.57B 5.77 $3.61B $5.17 38.77

Is TECH or DHR more profitable?

Danaher has a net margin of 14.89% compared to Bio-Techne's net margin of 9.05%. Bio-Techne's return on equity of 13.57% beat Danaher's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 9.05% 13.57% 10.66% Danaher 14.89% 10.91% 6.94%

Does the media refer more to TECH or DHR?

In the previous week, Danaher had 16 more articles in the media than Bio-Techne. MarketBeat recorded 23 mentions for Danaher and 7 mentions for Bio-Techne. Danaher's average media sentiment score of 1.11 beat Bio-Techne's score of 0.53 indicating that Danaher is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Danaher 17 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Bio-Techne (TECH) Competitors

$71.36 +0.06 (+0.08%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$71.42 +0.06 (+0.08%)

As of 07/13/2026 07:47 PM Eastern

Compare

TECH vs. BRKR, A, BIO, CRL, and DHR

Should you buy Bio-Techne stock or one of its competitors? MarketBeat compares Bio-Techne with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Techne include Bruker (BRKR), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), and Danaher (DHR).

How does Bio-Techne compare to Bruker?

Bruker (NASDAQ:BRKR) and Bio-Techne (NASDAQ:TECH) are both life sciences tools & services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.61	-$8.60M	-$0.24	N/A
Bio-Techne	$1.22B	9.16	$73.40M	$0.69	103.42

Bio-Techne has a net margin of 9.05% compared to Bruker's net margin of -0.65%. Bio-Techne's return on equity of 13.57% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-0.65%	11.60%	4.25%
Bio-Techne	9.05%	13.57%	10.66%

In the previous week, Bio-Techne had 2 more articles in the media than Bruker. MarketBeat recorded 7 mentions for Bio-Techne and 5 mentions for Bruker. Bruker's average media sentiment score of 1.63 beat Bio-Techne's score of 0.53 indicating that Bruker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bio-Techne	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bruker presently has a consensus target price of $56.79, suggesting a potential downside of 3.70%. Bio-Techne has a consensus target price of $68.08, suggesting a potential downside of 4.60%. Given Bruker's stronger consensus rating and higher possible upside, equities analysts clearly believe Bruker is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12

79.5% of Bruker shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 27.2% of Bruker shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bruker has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Bruker pays out -83.3% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Bio-Techne beats Bruker on 10 of the 18 factors compared between the two stocks.

How does Bio-Techne compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Agilent Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

99.0% of Bio-Techne shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.8%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	5.45	$1.30B	$4.98	26.91
Bio-Techne	$1.22B	9.16	$73.40M	$0.69	103.42

Agilent Technologies presently has a consensus target price of $159.35, suggesting a potential upside of 18.92%. Bio-Techne has a consensus target price of $68.08, suggesting a potential downside of 4.60%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Agilent Technologies is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12

Agilent Technologies has a net margin of 19.55% compared to Bio-Techne's net margin of 9.05%. Agilent Technologies' return on equity of 24.33% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Bio-Techne	9.05%	13.57%	10.66%

In the previous week, Agilent Technologies had 6 more articles in the media than Bio-Techne. MarketBeat recorded 13 mentions for Agilent Technologies and 7 mentions for Bio-Techne. Agilent Technologies' average media sentiment score of 0.90 beat Bio-Techne's score of 0.53 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Agilent Technologies beats Bio-Techne on 15 of the 20 factors compared between the two stocks.

How does Bio-Techne compare to Bio-Rad Laboratories?

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

In the previous week, Bio-Techne had 7 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 7 mentions for Bio-Techne and 0 mentions for Bio-Rad Laboratories. Bio-Techne's average media sentiment score of 0.53 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Techne	Positive
Bio-Rad Laboratories	Neutral

Bio-Techne has a net margin of 9.05% compared to Bio-Rad Laboratories' net margin of 6.52%. Bio-Techne's return on equity of 13.57% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bio-Techne presently has a consensus target price of $68.08, indicating a potential downside of 4.60%. Bio-Rad Laboratories has a consensus target price of $303.33, indicating a potential upside of 2.10%. Given Bio-Rad Laboratories' higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.16	$73.40M	$0.69	103.42
Bio-Rad Laboratories	$2.58B	3.08	$759.90M	$6.07	48.95

Bio-Techne has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Summary

Bio-Techne beats Bio-Rad Laboratories on 11 of the 16 factors compared between the two stocks.

How does Bio-Techne compare to Charles River Laboratories International?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Bio-Techne and Bio-Techne both had 7 articles in the media. Charles River Laboratories International's average media sentiment score of 1.13 beat Bio-Techne's score of 0.53 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.16	$73.40M	$0.69	103.42
Charles River Laboratories International	$4.02B	2.76	-$144.34M	-$3.76	N/A

Bio-Techne has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Bio-Techne currently has a consensus target price of $68.08, suggesting a potential downside of 4.60%. Charles River Laboratories International has a consensus target price of $220.75, suggesting a potential downside of 4.01%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Bio-Techne and Charles River Laboratories International tied by winning 7 of the 14 factors compared between the two stocks.

How does Bio-Techne compare to Danaher?

Bio-Techne (NASDAQ:TECH) and Danaher (NYSE:DHR) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 79.1% of Danaher shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Comparatively, 10.8% of Danaher shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Danaher had 16 more articles in the media than Bio-Techne. MarketBeat recorded 23 mentions for Danaher and 7 mentions for Bio-Techne. Danaher's average media sentiment score of 1.11 beat Bio-Techne's score of 0.53 indicating that Danaher is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Danaher	17 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Danaher has a net margin of 14.89% compared to Bio-Techne's net margin of 9.05%. Bio-Techne's return on equity of 13.57% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Danaher	14.89%	10.91%	6.94%

Bio-Techne has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Danaher has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.16	$73.40M	$0.69	103.42
Danaher	$24.57B	5.77	$3.61B	$5.17	38.77

Bio-Techne currently has a consensus target price of $68.08, indicating a potential downside of 4.60%. Danaher has a consensus target price of $231.64, indicating a potential upside of 15.56%. Given Danaher's stronger consensus rating and higher probable upside, analysts plainly believe Danaher is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Danaher	1 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.79

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Danaher pays out 30.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has raised its dividend for 2 consecutive years. Danaher is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Danaher beats Bio-Techne on 14 of the 20 factors compared between the two stocks.

Get Bio-Techne News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECH vs. The Competition

Export

Metric	Bio-Techne	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.16B	$3.71B	$7.05B	$12.61B
Dividend Yield	0.45%	2.20%	2.68%	8.00%
P/E Ratio	103.42	20.85	27.11	24.26
Price / Sales	9.16	314.01	587.92	117.88
Price / Cash	29.16	61.98	29.22	49.36
Price / Book	5.83	8.49	10.75	6.29
Net Income	$73.40M	$23.83M	$3.58B	$330.66M
7 Day Performance	1.06%	-3.56%	-2.06%	-1.32%
1 Month Performance	32.15%	6.31%	3.32%	-0.64%
1 Year Performance	35.61%	48.30%	26.35%	19.08%

Bio-Techne Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECH Bio-Techne	2.1725 of 5 stars	$71.36 +0.1%	$68.08 -4.6%	+31.8%	$11.16B	$1.22B	103.42	3,100
BRKR Bruker	3.0526 of 5 stars	$61.34 -0.5%	$54.54 -11.1%	+34.7%	$9.38B	$3.44B	N/A	11,085	Positive News
A Agilent Technologies	4.9234 of 5 stars	$130.78 +0.1%	$160.88 +23.0%	+8.6%	$36.91B	$6.95B	26.26	18,100
BIO Bio-Rad Laboratories	0.3984 of 5 stars	$294.88 -0.7%	$303.33 +2.9%	+15.5%	$7.94B	$2.59B	48.58	7,450	Positive News
CRL Charles River Laboratories International	1.808 of 5 stars	$231.54 +0.4%	$215.88 -6.8%	+43.9%	$11.11B	$4.02B	N/A	19,700	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECH) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Competitors

TECH vs. BRKR, A, BIO, CRL, and DHR

How does Bio-Techne compare to Bruker?

Summary

How does Bio-Techne compare to Agilent Technologies?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Summary

How does Bio-Techne compare to Danaher?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Competitors

TECH vs. BRKR, A, BIO, CRL, and DHR

How does Bio-Techne compare to Bruker?

Which has preferable valuation and earnings, BRKR or TECH?

Is BRKR or TECH more profitable?

Does the media refer more to BRKR or TECH?

Do analysts rate BRKR or TECH?

Do institutionals and insiders believe in BRKR or TECH?

Which has more risk and volatility, BRKR or TECH?

Is BRKR or TECH a better dividend stock?

Summary

How does Bio-Techne compare to Agilent Technologies?

Which has more volatility and risk, A or TECH?

Do institutionals & insiders have more ownership in A or TECH?

Is A or TECH a better dividend stock?

Which has better valuation & earnings, A or TECH?

Do analysts recommend A or TECH?

Is A or TECH more profitable?

Does the media prefer A or TECH?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Does the media favor TECH or BIO?

Is TECH or BIO more profitable?

Do insiders & institutionals believe in TECH or BIO?

Do analysts recommend TECH or BIO?

Which has preferable valuation and earnings, TECH or BIO?

Which has more volatility and risk, TECH or BIO?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Do institutionals & insiders have more ownership in TECH or CRL?

Does the media prefer TECH or CRL?

Is TECH or CRL more profitable?

Which has preferable earnings and valuation, TECH or CRL?

Which has more volatility & risk, TECH or CRL?

Do analysts recommend TECH or CRL?

Summary

How does Bio-Techne compare to Danaher?

Do insiders & institutionals have more ownership in TECH or DHR?

Does the media refer more to TECH or DHR?

Is TECH or DHR more profitable?

Which has more volatility and risk, TECH or DHR?

Which has stronger earnings & valuation, TECH or DHR?

Do analysts rate TECH or DHR?

Is TECH or DHR a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools